Institutional Investor OrbiMed Files Intent to Sell $38.3M in Enliven Therapeutics Stock
ELVN has more than doubled off its 52-week low of $14.785 on elevated volume (1.9× avg).
Summary
A major institutional shareholder, OrbiMed, plans to sell $38.3 million of Enliven Therapeutics stock, adding to recent insider distribution despite positive company news and a large capital raise.
Key Events · Ownership and Investor Activity · ELVN
-
Proposed Stock Sale
OrbiMed Private Investments VII, LP, a major shareholder, intends to sell 833,800 shares of common stock, valued at approximately $38.3 million.
-
Recent Sales by Filer
The same filer has already sold 272,322 shares for $12.3 million in the past three months, including sales after the recent positive clinical data and public offering.
-
Institutional Investor Activity
This filing indicates a significant reduction in holdings by a large institutional investor.
-
Follows Recent Positive News
The intent to sell comes shortly after Enliven Therapeutics announced positive Phase 1 data for ELVN-001 and completed an upsized $400 million public offering.
Analysis · ELVN · Life Sciences
OrbiMed Private Investments VII, LP, a significant institutional shareholder, has filed a Form 144 indicating its intent to sell approximately $38.3 million worth of Enliven Therapeutics common stock. This proposed sale follows recent positive Phase 1 data and a $400 million public offering, suggesting a strategic reduction in exposure by a major investor despite recent positive developments.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELVN was trading at $45.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $14.79 to $48.53. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.